Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $29.12M rose 44.4% year over year, ahead of the +16.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 39.8% from the prior quarter. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • Selling, general & admin amounted to 34.5% of revenue in FY2025, down 12.6 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $103.25M (+11.7%) for the fiscal year ending Dec 2026, a slowdown from the +17.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$29.12M+39.8% QoQ
Last fiscal yearDec 2025
$92.45M+17.5% YoY
LTMJun 2026
$103.43M+16.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.4%-4.3%-48.6 pp
1 year+17.5%+11.7%-5.9 pp
3-year CAGR+9.7%+20.4%+10.8 pp
5-year CAGR+20.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
92.45M USD
Year-over-year change
+17.5%
4-year CAGR
+18.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's LTM Jun 2026 selling, general & admin of $103.43M is the lowest of the 10 companies compared; the peer median is $1.4B.
  • Its year-over-year change of +16.1% is the highest of 9, against a peer median of +4.4%.
  • Selling, general & admin amounts to 35.6% of revenue for LGND, versus a peer median of 21.9%.
LGND Competitors Peer median
Selling, General & Admin for LGND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABBVAbbVie Inc.LTM Sep 2026$15.19B +8.7%-2.8%23.0%
PFEPfizer Inc.LTM Jun 2026$13.72B -1.7%+0.3%21.5%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$7.41B -0.0%-2.4%15.1%
AMGNAmgen Inc.LTM Jun 2026$7B +1.8%+9.2%18.4%
INCYIncyte CorporationLTM Jun 2026$1.4B +8.2%+11.2%24.0%
GMABGenmab A/SLTM Jun 2026$726.99M —-39.2%17.6%
EXELExelixis, Inc.LTM Jul 2026$533.92M +3.0%+4.1%21.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$337.33M +6.9%+29.8%35.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$118.84M +5.8%+1.0%39.6%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$103.43M +16.1%+9.7%35.6%
Peer median (excluding LGND) $1.4B+4.4%+1.0%21.9%

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.54M196.25M131.31M167.13M268.09M
Cost of Revenue62.18M52.83M35.05M11.07M6.59M
Gross Profit179.37M143.42M96.27M156.06M261.5M
Gross Margin74.3%73.1%73.3%93.4%97.5%
Research & Development32.11M36.08M24.54M21.43M81.18M
Selling, General & Admin46.79M70.06M52.79M78.65M92.45M
Operating Expenses75.52M140.38M84.32M178.67M214.3M
Depreciation & Amortization50.95M43.39M36.52M35.24M33.78M
EBITDA142.77M81.2M100.84M40.79M192.74M
EBITDA Margin59.1%41.4%76.8%24.4%71.9%
Operating Income103.85M3.04M11.94M(22.61M)47.2M
Operating Margin43.0%1.5%9.1%-13.5%17.6%
Interest Income886K2.05M7.71M8.06M13.66M
Interest Expense19.62M1.8M656K3.04M4.72M
Other Income / Expenses(31.65M)32.97M51.72M25.12M111.76M
Income Before Tax72.21M36.01M63.66M2.52M158.96M
Pre-Tax Margin29.9%18.4%48.5%1.5%59.3%
Income Tax Expense(4.15M)41.23M9.84M6.55M34.51M
Net Income57.14M(33.36M)52.15M(4.03M)124.45M
Net Margin23.7%-17.0%39.7%-2.4%46.4%
EPS (Basic)3.46(1.98)3.02(0.22)6.44
EPS (Diluted)3.34(1.98)2.94(0.22)6.13
Weighted Avg Shares16.63M16.87M17.3M18.29M19.34M
Weighted Avg Shares (Diluted)17.25M16.87M17.76M18.29M20.29M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.